Negative Impact of Vitamin D Deficiency at Diagnosis on Breast Cancer Survival: A Prospective Cohort Study

被引:2
作者
Almeida-Filho, Benedito Souza [1 ,2 ]
Omodei, Michelle Sako [1 ,2 ]
Buttros, Daniel A. B. [1 ,3 ]
Carvalho-Pessoa, Eduardo [1 ,2 ]
Carvalho-Pessoa, Carla Priscila [2 ]
Vespoli, Heloisa De Luca [2 ]
Nahas, Eliana Aguiar Petri [1 ,2 ]
机构
[1] Sao Paulo State Univ UNESP, Botucatu Med Sch, Grad Program Tocogynecol, Botucatu, SP, Brazil
[2] Sao Paulo State Univ UNESP, Botucatu Med Sch, Dept Gynecol & Obstet, Botucatu, SP, Brazil
[3] Rio Claro Univ Ctr, Claretian Sch Med, Rio Claro, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
25-HYDROXYVITAMIN D LEVELS; CLINICAL ONCOLOGY/COLLEGE; TUMOR CHARACTERISTICS; AMERICAN SOCIETY; METAANALYSIS; RISK; PROGNOSIS; RECOMMENDATIONS; ASSOCIATION; MORTALITY;
D O I
10.1155/2022/4625233
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. We prospectively evaluated the association between vitamin D concentration at diagnosis and overall survival (OS), disease-free survival (DFS), and cancer-specific survival (CSS) in postmenopausal women treated for breast cancer. Methods. This study included 192 patients newly diagnosed with invasive breast cancer, aged >= 45 years, and serum 25-hydroxy vitamin D (25 (OH)D) concentration assessment at diagnosis. Patients were classified into groups according to 25 (OH)D concentrations: sufficient (>= 30 ng/mL), insufficient (between 20 and 29 ng/mL), and deficient (< 20 ng/mL). The primary outcome was OS, and the secondary outcomes were DFS and CSS. The Kaplan-Meier curve and Cox regression model were used to assess the association between 25 (OH)D concentrations and survival rates. Differences in survival were evaluated by hazard ratios (HRs). Results. The mean age was 61.3 +/- 9.6 years, 25 (OH)D concentration was 26.9 +/- 7.5 ng/mL (range 12.0-59.2 ng/mL), and the follow-up period was between 54 and 78 months. Sufficient 25 (OH)D was detected in 33.9% of patients, insufficient in 47.9%, and deficient in 18.2%. A total of 51 patients (26.6%) died during the study period, with a mean OS time of 54.4 +/- 20.2 months (range 9-78 months). Patients with 25 (OH)D deficiency and insufficiency at diagnosis had a significantly lower OS, DFS, and CSS compared with patients with sufficient values (p < 0.001). After adjustment for clinical and tumoral prognostic factors, patients with 25 (OH)D concentrations considered deficient at diagnosis had a significantly higher risk of global death (HR, 4.65; 95% CI, 1.65-13.12), higher risk of disease recurrence (HR, 6.87; 95% CI, 2.35-21.18), and higher risk of death from the disease (HR, 5.91; 95% CI, 1.98-17.60) than the group with sufficient 25(OH)D concentrations. Conclusion. In postmenopausal women treated for breast cancer, vitamin D deficiency and insufficiency at diagnosis were independently associated with lower OS, DFS, and CSS compared with patients with sufficient 25(OH)D concentrations.
引用
收藏
页数:9
相关论文
共 47 条
[31]   Vitamin D Insufficiency. [J].
Rosen, Clifford J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (03) :248-254
[32]   Vitamin D3 signaling and breast cancer: Insights from transgenic mouse models [J].
Sheng, Lei ;
Callen, David F. ;
Turner, Andrew G. .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2018, 178 :348-353
[33]   Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study [J].
Simon, Sergio Daniel ;
Bines, Jose ;
Werutsky, Gustavo ;
Nunes, Joao Soares ;
Pacheco, Fernando Chalu ;
Segalla, Jose Getulio ;
Gomes, Andrea J. S. ;
Adam Van Eyll, Brigitte Marie H. R. ;
Gimenes, Daniel Luiz ;
Crocamo, Susanne ;
Freitas-Junior, Ruffo ;
Dal Lago, Lissandra ;
Queiroz, Geraldo Silva ;
de Azevedo, Sergio Jobim ;
Rosa, Daniela Dornelles ;
Delgado, Gilson ;
Borges, Giuliano Santos ;
do Nascimento, Yeni Veronica ;
Zaffaroni, Facundo ;
Martinez-Mesa, Jeovany ;
Barrios, Carlos H. E. .
BREAST, 2019, 44 :113-119
[34]   Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients [J].
Stuart-Harris, R. ;
Caldas, C. ;
Pinder, S. E. ;
Pharoah, P. .
BREAST, 2008, 17 (04) :323-334
[35]   Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review [J].
Szymiczek, Agata ;
Lone, Amna ;
Akbari, Mohammad R. .
CLINICAL GENETICS, 2021, 99 (05) :613-637
[36]  
Thanasitthichai Somchai, 2019, Asian Pac J Cancer Prev, V20, P3101, DOI 10.31557/APJCP.2019.20.10.3101
[37]   Circulating 25-hydroxyvitamin D Levels and Prognosis among Cancer Patients: A Systematic Review [J].
Toriola, Adetunji T. ;
Nhi Nguyen ;
Scheitler-Ring, Kristen ;
Colditz, Graham A. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2014, 23 (06) :917-933
[38]   Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study [J].
Tretli, Steinar ;
Schwartz, Gary G. ;
Torjesen, Peter Abusdal ;
Robsahm, Trude Eid .
CANCER CAUSES & CONTROL, 2012, 23 (02) :363-370
[39]   Associations of serum 25-hydroxyvitamin D with overall and breast cancer-specific mortality in a multiethnic cohort of breast cancer survivors [J].
Villasenor, Adriana ;
Ballard-Barbash, Rachel ;
Ambs, Anita ;
Bernstein, Leslie ;
Baumgartner, Kathy ;
Baumgartner, Richard ;
Ulrich, Cornelia M. ;
Hollis, Bruce W. ;
McTiernan, Anne ;
Neuhouser, Marian L. .
CANCER CAUSES & CONTROL, 2013, 24 (04) :759-767
[40]  
Voutsadakis Ioannis A, 2021, Hematol Oncol Stem Cell Ther, V14, P16, DOI 10.1016/j.hemonc.2020.08.005